TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8(+) T Cells in Hepatocellular Carcinoma

BACKGROUND & AIMS: TIGIT is a co-inhibitory receptor, and its suitability as a target for cancer immunotherapy in HCC is unknown. PD1 blockade is clinically effective in about 20% of advanced HCC patients. Here we aim to determine whether co-blockade of TIGIT/PD1 has added value to restore funct...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Mol Gastroenterol Hepatol
Hlavní autoři: Ge, Zhouhong, Zhou, Guoying, Campos Carrascosa, Lucia, Gausvik, Erik, Boor, Patrick P.C., Noordam, Lisanne, Doukas, Michael, Polak, Wojciech G., Terkivatan, Türkan, Pan, Qiuwei, Takkenberg, R. Bart, Verheij, Joanne, Erdmann, Joris I., IJzermans, Jan N.M., Peppelenbosch, Maikel P., Kraan, Jaco, Kwekkeboom, Jaap, Sprengers, Dave
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2021
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8255944/
https://ncbi.nlm.nih.gov/pubmed/33781741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcmgh.2021.03.003
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky